| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| Other Sizes |
|
| ln Vitro |
TM-25659 (2, 10, 20, 100 μM) promotes intranuclear TAZ localization in an intermittent manner and opens PPARγ-mediated adipocyte gaps by enhancing the PPARγ inhibitory action of TAZ [1]. TM-25659 (2, 10, 50 μM) promotes osteogenic gene expression, hence boosting osteoblast secretion [1].
|
|---|---|
| ln Vivo |
In vivo in cyclohexane buffer, TM-25659 (50 mg/kg, intraperitoneally, every other day for two weeks) decreases body weight gain in prepared models [1]. In solution, TM-25659 has favorable pharmacokinetics. The rope concentration of TM-25659 recovers with a t1/2 of approximately 7 or 10 hours after iv or po, respectively. Systemic clearance (CL) is 0.21 L × h-1 × kg-1, repeated distribution
|
| Cell Assay |
Cell proliferation analysis[1]
Cell Types: 3T3-L1 Cell Tested Concentrations: 2, 10, 20, 100 μM Incubation Duration: 6 days Experimental Results: Acts as an inhibitor of PPARγ-dependent adipocyte differentiation[1]. |
| Animal Protocol |
Animal/Disease Models: C57BL6 mice (4- to 6 weeks old) [1]
Doses: 50 mg/kg Route of Administration: Ip, every The next day, for 2 weeks, Experimental Results: these obese mice had attenuated weight gain [1]. Animal/Disease Models: Adult male SD (SD (Sprague-Dawley)) rat [1] Doses: 10 mg/kg Route of Administration: intravenous (iv) (iv)(2, 10 and 30 minutes), oral (15 and 30 minutes and 1, 2, 4 and 8 hrs (hrs (hours))) Experimental Results: After 4 weeks of oral administration, the weight gain of OVX rats was moderately but Dramatically attenuated, and BMD was partially restored [1]. |
| References |
| Molecular Formula |
C30H28N8
|
|---|---|
| Molecular Weight |
500.596924781799
|
| Exact Mass |
500.243
|
| CAS # |
260553-97-7
|
| PubChem CID |
49821008
|
| Appearance |
White to off-white solid powder
|
| LogP |
5.8
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
38
|
| Complexity |
729
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
KCOQNLYGMQJUJD-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C30H28N8/c1-3-4-11-28-33-27-17-26(23-8-7-16-31-18-23)20(2)32-30(27)38(28)19-21-12-14-22(15-13-21)24-9-5-6-10-25(24)29-34-36-37-35-29/h5-10,12-18H,3-4,11,19H2,1-2H3,(H,34,35,36,37)
|
| Chemical Name |
2-butyl-5-methyl-6-pyridin-3-yl-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazo[4,5-b]pyridine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 135 mg/mL (~269.68 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.25 mg/mL (4.49 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 22.5 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.25 mg/mL (4.49 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 22.5 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.25 mg/mL (4.49 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.9976 mL | 9.9880 mL | 19.9760 mL | |
| 5 mM | 0.3995 mL | 1.9976 mL | 3.9952 mL | |
| 10 mM | 0.1998 mL | 0.9988 mL | 1.9976 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
